Novacyt S.A. (FRA:NYZ)

Market Cap	28.77M -19.2%
Revenue (ttm)	22.96M +2.0%
Net Income	-26.23M
EPS	-0.37
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4170
Previous Close	0.3870
Day's Range	0.4170 - 0.4170
52-Week Range	0.2930 - 0.9680
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 3, 2026

About Novacyt

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 216
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NYZ

Financial Performance

In 2025, Novacyt's revenue was 20.03 million, an increase of 2.03% compared to the previous year's 19.63 million. Losses were -22.88 million, -45.20% less than in 2024.

Financial numbers in GBP

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error